Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Monash University | OTHER |
| Sydney Local Health District | OTHER_GOV |
Not provided
Not provided
Not provided
Not provided
To explore the effectiveness of of MDMA-assisted prolonged exposure therapy in improving treatment outcomes for individuals with comorbid PTSD and alcohol use disorder in a double-blind randomised placebo-controlled trial.
New strategies for the treatment of comorbid PTSD and alcohol dependence are urgently required. Recent evidence has shown strong support for trauma-focused integrated treatments (namely COPE), however, only 49% demonstrate clinically significant improvements. MDMA may be a promising approach to improve response to COPE for this population. Emerging evidence suggests that MDMA-assisted therapy may be of promise for PTSD, and has demonstrated a good safety profile and potential efficacy in alcohol dependence.
This project will evaluate the clinical efficacy and tolerability of MDMA-assisted COPE relative to a control-assisted COPE. Active control used in this study is niacin. The investigators hypothesise that MDMA treated participants will be have a reduction in PTSD symptom severity as well as heavy drinking.
The trial will utilise a double blind, randomised, controlled design. A sample of 120 individuals will receive 14 weeks of treatment including 12 COPE sessions and 2 dosing sessions with MDMA (80-160mg) or control (niacin 250mg).
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| COPE + MDMA | Experimental | 4x COPE sessions Dose 1: 2x MDMA capsules (80mg) + 1x niacin-matched placebo capsule Optional supplementary dispense: 1x MDMA capsule (40mg) 4x COPE sessions Dose 2: 2x MDMA capsules (80mg) + 1x niacin-matched placebo capsule Optional supplementary dispense: 1x OR 2x white MDMA capsule (40 or 80mg) 4x COPE sessions |
|
| COPE + Niacin (Control) | Other | 4x COPE sessions Dose 1: 2x MDMA-matched placebo capsules + 1x niacin capsule (250mg) Optional supplementary dispense: 1x MDMA-matched placebo capsule 4x COPE sessions Dose 2: 2x MDMA-matched placebo capsules + 1x niacin capsule (250mg) Optional supplementary dispense: 1x OR 2x MDMA-matched placebo capsule 4x COPE sessions |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Prolonged exposure therapy | Behavioral | COPE represents an integration of existing evidence-based manualised CBT interventions for PTSD and substance dependence (see manual DOI: 10.1093/med:psych/9780199334513.001.0001). COPE used in the current study will represent an integration of existing evidence-based manualised CBT interventions for PTSD and substance dependence. COPE only begins when the participant in a safe environment and no longer in contact with the traumatic event/exposure. COPE employs imaginal and in vivo exposures to treat PTSD and consists of 12 individual 90-minute sessions (i.e. 19.5 hours) delivered by a clinical psychologist. |
| Measure | Description | Time Frame |
|---|---|---|
| change in clinician-rated PTSD severity via Clinician-Administered PTSD Scale for DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition) (CAPS-5) from baseline to visit 16. | CAPS-5 is a structured diagnostic interview with excellent psychometric properties and diagnostic efficiency and used widely in MDMA-assisted PTSD studies. The CAPS-5 will be administered by independent evaluators blind to treatment condition. CAPS-5 total symptom severity score is calculated by summing severity scores for the 20 DSM-5 PTSD symptoms. CAPS-5 symptom cluster severity scores are calculated by summing the individual item severity scores for symptoms corresponding to a given DSM-5 cluster: Criterion B (items 1-5); Criterion C (items 6-7); Criterion D (items 8-14); and, Criterion E (items 15-20). | 52 weeks |
| change in self-reported PTSD symptom severity via Post-Traumatic Stress Disorder Checklist for DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition) (PCL-5) from baseline to visit 16. | PCL-5 has excellent psychometric characteristics for a secondary indicator of PTSD symptom severity. Items are summed to provide a total severity score (range = 0-80). The PCL-5 can determine a provisional diagnosis in two ways: Summing all 20 items (range 0-80) and using a cut-point score of 31-33 appears to be reasonable based upon current psychometric work. | 52 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Heavy Drinking Days per week (HDDs) (>5 standard drinks/day for men; >4 for women) | This will be measured by the Timeline Follow Back and corroborated with Phosphatidylethanol (PEth) levels | 52 weeks |
| Absence of any HDD |
| Measure | Description | Time Frame |
|---|---|---|
| Mean alcohol consumption per drinking day | Measured by Timeline Follow Back and corroborated with Phosphatidylethanol (PEth) levels | 52 weeks |
| Change in dependence Severity | Measured by the Alcohol Dependence Scale. The minimum score is 0 and the maximum score is 47. A higher score indicates more severe dependence. |
Inclusion Criteria:
Exclusion Criteria:
History of, or currently meeting, DSM-5 criteria for:
Pregnant or lactating (contraception must be used and a sensitive pregnancy test will be performed at baseline and prior to dosing)
Significant alcohol withdrawal (current Clinical Institute Withdrawal Assessment for Alcohol [CIWA-Ar] score ≥10, including history of delirium tremens or alcohol withdrawal seizures).
Concurrent use of psychotropic medication (antidepressants and alcohol pharmacotherapy use considered if assessed by physician and titrated down with 5 half-lives + 1 week washout)
Use of, and unable or unwilling to cease, any medications likely to interact with MDMA in the opinion of the physicians and investigators during the trial (low dose opiates are permitted for pain management but not the night before or after MDMA sessions)
Substance use disorder other than tobacco (e.g. benzodiazepines, cannabis)
Abnormal clinical findings including a history of, or current: cardiac disease and/or dysrhythmia, uncontrolled hypertension or severe hypotension, abnormal electrocardiogram findings, stroke, liver disease, a history of epilepsy, hyponatraemia, or malignant hyperthermia (controlled hypertension and diabetes type II may be permitted)
Suicide risk according to clinician judgement and responses to Columbia Suicide Severity Rating Scale-Lifetime (C-SSRS-L) and SCID-5-RV.
• Details surrounding any previous attempts >6 months ago will be gathered whereby attempts related to their trauma/PTSD and/or associated with the use of psychostimulants will contribute to risk assessment and guide trial safety measures if enrolled
Clinically unstable systemic medical (e.g., cancer) or psychiatric disorder or condition that might require hospitalisation that precludes trial participation
Regular use of ecstasy (e.g. at least twice in last 6 months, or >10 times within the last 5 years)
Enrolled in any other interventional clinical trials in the previous two months or over the duration of the study
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Kirsten C Morley, PhD | Contact | 61295153636 | Kirsten.morley@sydney.edu.au | |
| Ellen Towers | Contact | ellen.towers@sydney.edu.au |
| Name | Affiliation | Role |
|---|---|---|
| Kirsten C Morley, PhD | University of Sydney | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Drug Health Services, Royal Prince Alfred Hospital | Recruiting | Sydney | New South Wales | 2050 | Australia |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 42409408 | Derived | Morley KC, Arunogiri S, Mills K, Watt J, Teesson M, Baillie A, Lee YY, Morse A, Back SE, Lubman DI, Haber PS. MDMA-assisted PTSD and Alcohol Therapy Trial (MPATHY): study protocol for a double-blind, randomised, controlled outpatient trial of MDMA-assisted integrated exposure-based therapy for comorbid post-traumatic stress disorder and alcohol use disorder. BMJ Open. 2026 Jul 6;16(7):e114896. doi: 10.1136/bmjopen-2025-114896. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Randomised, double-blind between group comparison of change in PTSD symptoms and alcohol consumption
Not provided
Not provided
Not provided
|
|
| MDMA | Drug | Administration of 80 to 160 mg MDMA across two 'dosing' sessions. Supplemental doses (additional 40mg during first session, additional 40- 80mg during second session) will be dependent on clinician and participant consensus during preparatory period of 'dosing session'. These supplemental amounts will be dispensed 60 to 90 minutes after initial 80 mg dose. |
|
|
| Niacin | Drug | Administration of niacin 250mg or niacin-matched placebo during two 'dosing' sessions. |
|
|
Measured by Timeline Follow Back and corroborated with Phosphatidylethanol (PEth) levels
| 52 weeks |
| 52 weeks |
| Changes in Anxiety | Measured by cumulative scores on the DASS-21 Anxiety Scale. This scale has a minimum score of 0 and maximum score of 21. A higher score indicates more anxiety. | 52 weeks |
| Changes in Depression | Measured by cumulative scores on the DASS-21 Depression Scale. This scale has a minimum score of 0 and maximum score of 21. A higher score indicates greater depression. | 52 weeks |
| Changes in Stress | Measured by cumulative scores on the DASS-21 Stress Scale. This scale has a minimum score of 0 and maximum score of 21. A higher score indicates more stress. | 52 weeks |
| Sleep Disturbances | As measured by the ISI (Insomnia Severity Index). This Index has a minimum score of 0 and a maximum score of 28. The higher the score indicates more severe insomnia. | 52 weeks |
| Drinking Diary | Daily texts will be sent out to participants querying the amount of alcohol they have consumed. Participant responses to this will be recorded. This will be managed through SEMA software. | 16 weeks |
| Mood states | Daily texts will be sent out to participants querying their moods. This will be in line with the POMS instrument (Profile of Mood States). | 16 weeks |
| Mood following dosing session | The week following each dosing session will involve calls with participants to complete POMS (profile of mood states) | week 5, week 10 |
| Changes in Suicidal Ideation | Changes in suicidal ideation & behaviours across the treatment period. This will be measured on the C-SRSS (Columbia Suicide Severity Rating Scale). At baseline this will be measured by the baseline version. At each visit following this, this will be recorded on the since last visit version. Higher scores indicate more severe suicidality. | 52 weeks |
| Changes in Quality of Life | To assess whether treatment can change quality of life as measured by the short form Health Survey (SF-36). This survey has 36 items that measure 8 domains of health, including: physical functioning, physical role limitations, bodily pain, general health perceptions, energy/vitality, social functioning, emotional role limitations and mental health. The scores are transformed to range from 0 (worst possible health) to 100 (best possible health). | 16 weeks |
| Changes PTSD cognitions | As measured by the PTCI. This is a 33 question inventory measures negative cognitions about the self & world, as well as self-blame. Higher scores indicate more negative cognitions. | 52 weeks |
| Changes in use of Health Services | As measured by the Brief Health Services Use Questionnaire. This questionnaire assesses Health Service Use across the last 3 months. It is a qualitative questionnaire. | 16 weeks |
| Therapeutic Alliance between therapist | As measured by the Helping Alliance Questionnaire (HAQ-II). This instrument will be completed by the patient (patient version) and the clinician (clinician version). This outlines how a person may feel or behave in relation to their therapist. Higher scores indicates a better therapeutic alliance. | 16 weeks |
| COPE Session Rating Scale | As measured by the session rating scale (SRS). Following each COPE session, both the therapist and participant will complete a brief post-session rating. This scale measures; relationship, goals & topics, approach or method and overall psychotherapy session. Higher scores on each of these indicate a more positive experience. | 16 weeks |
| Treatment Satisfaction as measured by the YES (your experience of service). | This instrument is designed to gather information from consumers about their experiences of care. | 16 weeks |
| Treatment Satisfaction ss measured by the CSQ-8 (client satisfaction questionnaire). | This instrument measures clients satisfaction with treatment. Total scores range from 8 to 32, with the higher number indicating greater satisfaction. | 16 weeks |
| Measurement of Distress ss measured by a Likert Scale | This instrument will be administered hourly within the dosing sessions. It aims to measure the participant's mood on a scale of 1 (worst) -10 (best) | week 5, week 12 |
| Measurement of Drug Effect as measured by the Revised Mystical Experience Questionnaire 30 (MEQ-30) | MEQ-30 Measures mystical, positive mood, transcendence, ineffability experienced in dosing sessions. MEQ-30 will be compelted at the end of each dosing session. participants will be asked to rate rate the degree to which at any time during that session they experienced certain phenomena on a scale of 0 (not at all) to 5 (more than any other time in their life) | week 5, week 12 |
| Turning Point | Not yet recruiting | Richmond | Victoria | 3121 | Australia |
|
| ID | Term |
|---|---|
| D013313 | Stress Disorders, Post-Traumatic |
| D000437 | Alcoholism |
| ID | Term |
|---|---|
| D040921 | Stress Disorders, Traumatic |
| D000068099 | Trauma and Stressor Related Disorders |
| D001523 | Mental Disorders |
| D019973 | Alcohol-Related Disorders |
| D019966 | Substance-Related Disorders |
| D064419 | Chemically-Induced Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D018817 | N-Methyl-3,4-methylenedioxyamphetamine |
| D009525 | Niacin |
| D009536 | Niacinamide |
| ID | Term |
|---|---|
| D000662 | Amphetamines |
| D010627 | Phenethylamines |
| D005021 | Ethylamines |
| D000588 | Amines |
| D009930 | Organic Chemicals |
| D009539 | Nicotinic Acids |
| D000147 | Acids, Heterocyclic |
| D006571 | Heterocyclic Compounds |
| D011725 | Pyridines |
| D006573 | Heterocyclic Compounds, 1-Ring |
Not provided
Not provided